Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This phase I trial is to find out the best dose, possible benefits and/or side effects of
lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in
patients with primary central nervous system (CNS) lymphoma. Lenalidomide may stop or slow
primary CNS lymphoma by blocking the growth of new blood vessels necessary for tumor growth.
Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune
system attack the cancer, and may interfere with the ability of cancer cells to grow and
spread. Rituximab is a monoclonal antibody that may interfere with the ability of cancer
cells to grow and spread. Methotrexate is frequently combined with other chemotherapy agents
to improve response. This study may help increase the understanding of lenalidomide and
nivolumab use in primary CNS lymphoma treatment. In addition, it may help researchers see
whether the control of CNS lymphoma can be extended by using these study drugs as maintenance
(prolonged therapy) after control is achieved with the initial chemotherapy regimen
(induction).